A study evaluated the genetic alterations associated with acquired resistance to PD-1 blockade in melanoma patients and it was reported a case of B2M mutations were present in resistant tumor cells and lead to a lack of surface expression of MHC class I [96]. The gene discussed is PDCD1; the disease is neoplasm.